AstraZeneca and Isis broaden antisense deal
This article was originally published in Scrip
Executive Summary
AstraZeneca and Isis Pharmaceuticals have expanded their alliance in the field of antisense therapies, with the UK major paying $65m up front to Isis as part of the agreement. They will collaborate to discover and develop new treatments for cardiovascular, metabolic and renal diseases, in a move that extends Isis's R&D into kidney disease, a new area for the company. The deal will also include development and regulatory milestones for each program that advances, as well as double-digit tiered royalties on net sales of any resulting products that are ultimately commercialized. The two companies first partnered to develop antisense therapies against cancer targets in 2012, in a collaboration that was worth $31m up front to Isis but which the company boasted could be ultimately worth in excess of $1bn. The following year that deal was expanded to include metabolic and cardiovascular indications. They later expanded their partnership to discover and develop novel delivery methods for antisense oligonucleotides in November 2014. The lead compound in the cancer collaboration, AZD9150/ISIS-STAT3-2.5
You may also be interested in...
AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition
Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth
Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.